Molecular origins of lung cancer: prospects for personalized prevention and therapy.

The first Meeting on "Molecular Origins of Lung Cancer--Prospects for Personalized Prevention and Therapy" was held from January 10 to 14, 2010 in San Diego, California. The purpose of the meeting was to discuss important basic, translational, and clinical work aimed at improving lung cancer prevention, detection, and treatment. Topics included drug design, target identification, early detection, cancer stem cells, microRNAs, genome wide approaches to determining risk and outcome, mouse models, and tumor microenvironment. The role of cancer advocates in supporting research was an important component of the meeting. Meeting presentations demonstrated that emerging technologies can molecularly dissect lung cancers that have important relevance for clinical utility. This includes molecular based strategies not only for treatment of established cancers but also individualized and molecularly-based strategies for cancer risk reduction and chemoprevention.

[1]  S. Toyooka,et al.  Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. , 2010, The Lancet. Oncology.

[2]  Curtis C. Harris,et al.  Microenvironmental modulation of asymmetric cell division in human lung cancer cells , 2010, Proceedings of the National Academy of Sciences.

[3]  Lin Huan,et al.  Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer , 2010 .

[4]  A. Lokshin,et al.  Elimination of human lung cancer stem cells through targeting of the stem cell factor-c-kit autocrine signaling loop. , 2010, Cancer research.

[5]  John R. Engen,et al.  Novel mutant-selective EGFR kinase inhibitors against EGFR T790M , 2009, Nature.

[6]  T. Mok,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.

[7]  Hua Yu,et al.  The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. , 2009, Cancer cell.

[8]  Kwok-Kin Wong,et al.  Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition , 2009, Proceedings of the National Academy of Sciences.

[9]  J. Lee,et al.  Snail Promotes CXCR2 LigandDependent Tumor Progression in NonSmall Cell Lung Carcinoma , 2009, Clinical Cancer Research.

[10]  A. Gualberto,et al.  Clinical development of inhibitors of the insulin-like growth factor receptor in oncology. , 2009, Current drug targets.

[11]  Alexander Pertsemlidis,et al.  Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. , 2009, Genes & development.

[12]  Y. Ishikawa,et al.  A mouse model for EML4-ALK-positive lung cancer , 2008, Proceedings of the National Academy of Sciences.

[13]  S. Narumiya,et al.  Prostacyclin Prevents Murine Lung Cancer Independent of the Membrane Receptor by Activation of Peroxisomal Proliferator–Activated Receptor γ , 2008, Cancer Prevention Research.

[14]  Steven Piantadosi,et al.  DNA methylation markers and early recurrence in stage I lung cancer. , 2008, The New England journal of medicine.

[15]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[16]  N. Donato,et al.  Abrogation of Signal Transducer and Activator of Transcription 3 Reactivation after Src Kinase Inhibition Results in Synergistic Antitumor Effects , 2007, Clinical Cancer Research.

[17]  Joon-Oh Park,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.

[18]  Y. Fukami,et al.  Tyrosine phosphorylation of p145met mediated by EGFR and Src is required for serum-independent survival of human bladder carcinoma cells , 2006, Journal of Cell Science.

[19]  Hua Yu,et al.  The STATs of cancer — new molecular targets come of age , 2004, Nature Reviews Cancer.